-
公开(公告)号：US20190202798A1
公开(公告)日：2019-07-04
申请号：US16296319
申请日：2019-03-08
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
-
公开(公告)号：US20190144429A1
公开(公告)日：2019-05-16
申请号：US16261689
申请日：2019-01-30
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Gõran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D405/14 , C07D413/14 , C07D403/04 , C07D487/04 , C07D471/04 , C07D417/14 , C07D413/04 , C07D407/14 , C07D401/04 , A61K31/5355 , A61K31/519 , A61K31/506 , A61K31/497 , A61K31/454
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
公开(公告)号：US11708360B2
公开(公告)日：2023-07-25
申请号：US17192968
申请日：2021-03-05
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
CPC classification number: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.-
公开(公告)号：US20180273504A1
公开(公告)日：2018-09-27
申请号：US15547228
申请日：2016-01-29
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand J. Unwalla
IPC: C07D401/04 , A61P29/00 , A61P37/06 , C07D401/14 , C07D417/14 , C07D405/14 , C07D413/14
CPC classification number: C07D401/04 , A61P29/00 , A61P37/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
-
公开(公告)号：US20150291554A1
公开(公告)日：2015-10-15
申请号：US14439478
申请日：2013-11-01
Applicant: PFIZER INC.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
CPC classification number: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Abstract translation: 本文公开的是与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。 公开了制备化合物的方法。 还公开了包含化合物的药物组合物。 公开了使用BTK抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫性疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症。
-
Patent Agency Ranking
公开(公告)号：US20240368144A1
公开(公告)日：2024-11-07
申请号：US18311266
申请日：2023-05-03
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号：US20210206757A1
公开(公告)日：2021-07-08
申请号：US17192968
申请日：2021-03-05
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号：US10815213B2
公开(公告)日：2020-10-27
申请号：US16296319
申请日：2019-03-08
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04 , C07D401/14 , A61K31/4155 , A61K31/454 , A61P29/00 , A61P35/00
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
-
公开(公告)号：US10426135B2
公开(公告)日：2019-10-01
申请号：US16268857
申请日：2019-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A01K5/01 , B65D77/20 , B65D25/04 , B65D1/34 , A01K7/00 , A23K20/00 , A23K50/48 , B65D1/36 , B65D25/18 , B65D85/00
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US20170283393A1
公开(公告)日：2017-10-05
申请号：US15624969
申请日：2017-06-16
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
CPC classification number: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.025 seconds)
